Multidrug resistance reversal agent, NSC77037, Identified with a cell-based screening assay

Journal of Biomolecular Screening

Volumn 15, Issue 3, 2010, Pages 287-296

  Susa, Michiro ^a   Choy, Edwin ^a   Yang, C A O ^a   Schwab, Joseph ^a   Mankin, Henry ^a   Hornicek, Francis ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cell based screening; Drug resistance; Nsc77037 tetrandrine; Pgp

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CALCEIN; CISPLATIN; CYCLOSPORIN A; CYTOTOXIC AGENT; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NSC 77037; PACLITAXEL; PM 00104; TETRANDRINE; TRABECTEDIN; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

ARTICLE; ASSAY; CANCER CELL; CANCER CELL CULTURE; CELL BASED SCREENING ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG SCREENING; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECTROPHOTOMETER; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATASES; BENZYLISOQUINOLINES; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCEINS; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; SUBSTRATE SPECIFICITY; TIME FACTORS; VERAPAMIL;

EID: 77949342231     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057109359422     Document Type: Article

References (38)

1. Dean M, Fojo T, Bates S: Tumour stem, cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
2. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
3. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-234.
4. Mellor HR, Callaghan R: Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 2008; 81: 275-300.
5. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV: Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003; 3: 1-19.
6. Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I: Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 1991; 88: 547-551.
7. Schurr E, Raymond M, Bell JC, Gros P: Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdrl cDNA. Cancer Res 1989; 49: 2729-2733.
8. Kaye SB: Reversal of drug resistance in ovarian cancer: where do we go from, here? J Clin Oncol 2008; 26: 2616-2618.
9. Ferry DR, Traunecker H, Kerr DJ: Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 1996; 32A: 1070-1081.
10. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell. BL, Allen SL, et al: Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 2004; 22: 4290-4301.
11. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ: P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999; 59: 3944-12948
12. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, et al: Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005; 104: 682-691.
13. Caldwell JS: Cancer cell-based genomic and small molecule screens. Adv CancerRes 2007; 96: 145-173.
14. Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, et al: 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct~2-ene-6,7-dicafboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol 2007; 72: 1137-1145.
15. Quesada AR, Barbacid MM, Mira E, Aracil M, Marquez G: Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal, agents. Cancer Lett 1996; 99: 109-114.
16. Duan Z, Choy E, Hornicek FJ: NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One 2009; 4: e7415.
17. Duan Z, Feller AJ, Toll HC, Makastorsis T, Seiden MV: TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 1999; 229: 75-81.
18. Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV: Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 2005; 55: 277-285.
19. Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, Horniček FJ: Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drag resistant cell lines. Cancer Chemother Pharmacol 2009; 63: 1121-1129.
20. Lamendola DE, Duan Z, Yusuf RZ, Seiden MV: Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 2003; 63: 2200-2205.
21. Carmichael J, DeGraff WG, Gazdar AF, Minna. JD, Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-942.
22. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, et al: Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996; 56: 4171-4179.
23. Liminga G, Nygren P, Larsson R: Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. Exp Cell Res 1994; 212: 291-296.
24. Nabekura T, Yamaki T, Ueno K, Kitagawa S : Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother Pharmacol 2008; 62: 867-873.
25. Ahmed-BelkacemA, PozzaA, Munoz-Martinez F, Bates SE, Castanys S, Gamarro F, et al: Flavonoid structure-activity studies identify 6prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 2005; 65: 4852-4860.
26. Garrigues A, Nugier J, Orlowski S, Ezan E: A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal Biochem 2002; 305: 106-114.
27. Litman T, Skovsgaard T, Stein WD: Pumping of drugs by P-glycoprotein: a two-step process? J Pharmacol Exp Ther 2003; 307: 846-853.
28. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398.
29. Dai CL, Xiong HY, Tang LF, Zhang X, Liang YJ, Zeng MS, et al: Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. Cancer Chemother Pharmacol 2007; 60: 741-750.
30. Fu L, Liang Y, Deng L, Ding Y, Chen L, Ye Y, et al: Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother Pharmacol 2004; 53: 349-356.
31. Schiff PL, Jr: Bisbenzylisoquinoline alkaloids. J Nat Prod 1987; 50: 529-599.
32. Jang BC, Lim KJ, Paik JH, Cho JW, Baek WK, Suh MH, et al: Tetrandrine-induced apoptosis is mediated by activation of caspases and PKC-delta in U937 cells. Biochem Pharmacol 2004; 67: 1819-1829.
33. Meng LH, Zhang H, Hayward L, Takemura H, Shao RG, Pommier Y: Tetrandrine induces early Gl arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G1-Sspecific cyclin-dependent kinases and by inducing p53 and p21Cipl. Cancer Res 2004; 64: 9086-9092.
34. Zhu X, Sui M, Fan W: In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Res 2005; 25: 1953-1962.
35. Xu WL, Shen HL, Ao ZF, Chen BA, Xia W, Gao F, et al: Combination of tetrandrine as a potential-reversing agent with daunorabicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk Res 2006; 30: 407-413.
36. Higgins CF: Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007; 446: 749-757.
37. Choi CH, Kim JH, Kim SH: Reversal of P-glycoprotein-mediated MDR by 5,7,3′ ,4′,5′-pentamethoxyflavone and SAR. Biochem Biophys Res Commun 2004; 320: 672-679.
38. Kitazaki T, Oka M, Nakamura Y, Tsuratani J, Doi S, Yasunaga M, et al: Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 2005; 49: 337-343.